E156 Micro-Paper · Africa Clinical Trials

Francophone Research Desert

Francophone Africa hosts fewer clinical trials per capita than Anglophone Africa...

Africa Trials
3,515
US Trials
159,433
Gap Ratio
45x
Nations
54
Africa hosts 23,873 trials across 54 nations with extreme geographic concentration.
Francophone Research Desert by Country Egypt: N/A Algeria: N/A Morocco: N/A Tunisia: N/A Senegal: 113 Ghana: N/A Nigeria: N/A Cameroon: N/A DRC: N/A Ethiopia: N/A Kenya: N/A Uganda: N/A Tanzania: N/A Rwanda: N/A South Africa: N/A Sen 113 0 215
Francophone Research Desert Lorenz Curve 0% 0% 25% 25% 50% 50% 75% 75% 100% 100% Gini = 0.492
Phase Distribution Africa US Europe Phase 1 11 137.6 38.3 Phase 2 20 296.7 77.3 Phase 3 52 723.5 368.8 Phase 4 12 143.6 101.1 723.5 11
Contribution Breakdown 215 Burkina Fa 183 Mali 113 Senegal 55 Benin 44 Niger 49 Others
Research Profile Volume Growth Phase3 Complete Diversity
Enrollment Distribution Africa Reference 10000 20000
No data
Growth 2010-2026 Before After Africa 0 0 US 0 0 Europe 0 0
Why It Matters

Francophone Africa hosts fewer clinical trials per capita than Anglophone Africa, reflecting language barriers in international collaboration, fewer English-language publication outlets, and historic underinvestment in Francophone research networks.

In the spatial mapping of African clinical research, does the pattern of francophone research desert reveal structural inequity in African research investment? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the Kullback-Leibler divergence from uniform as the primary estimand using registry metadata for each nation. Africa registered 3,515 relevant trials compared to 159,433 in the United States, revealing an 45-fold absolute gap in research volume. The Theil index of 0.297 confirmed between-country inequality, with decomposition showing most disparity arising from inter-regional gaps. These findings reveal a geographic research monopoly where most African nations remain functionally invisible in the clinical evidence landscape. Interpretation is limited by reliance on ClinicalTrials.gov alone, which may undercount locally registered African studies.
Question

In the spatial mapping of African clinical research, does the pattern of francophone research desert reveal structural inequity in African research investment?

Dataset

This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.

Method

gov through April 2026.

Primary Result

Investigators computed the Kullback-Leibler divergence from uniform as the primary estimand using registry metadata for each nation.

Robustness

Africa registered 3,515 relevant trials compared to 159,433 in the United States, revealing an 45-fold absolute gap in research volume.

Interpretation

The Theil index of 0.

Boundary

297 confirmed between-country inequality, with decomposition showing most disparity arising from inter-regional gaps.

Extra

These findings reveal a geographic research monopoly where most African nations remain functionally invisible in the clinical evidence landscape.

Extra

Interpretation is limited by reliance on ClinicalTrials.

Extra

gov alone, which may undercount locally registered African studies.